O ystyried bod 'Policy Position: Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis' i fod i gael ei adolygu ym mis Awst 2017, pryd y mae Ysgrifennydd y Cabinet yn disgwyl i Bwyllgor Gwasanaethau Iechyd Arbenigol Cymru gwblhau ei adolygiad fel bod ganddo bolisi cyfredol i seilio penderfyniadau am drin cleifion o Gymru arni?
August 2017 was the earliest commencement date for the Welsh Health Specialised Services Committee (WHSSC) to review their commissioning policy for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis.
CRS and HIPEC is already a treatment option for pseudomyxoma peritonei and available under extant WHSSC policy.
WHSSC intend to produce an overarching CRS and HIPEC policy for all peritoneal malignancies and have commissioned the Cedar Health Technology Research Centre to review the evidence on the clinical and cost effectiveness of CRS and HIPEC for both peritoneal carcinomatosis and pseudomyxoma peritonei.
The review is expected to complete in May 2018.